Elyra 7 Microscope with Lattice SIM2

项目总结/摘要 UCSD医学院显微镜核心是校园内最大的光学显微镜核心设施， 为加州大学圣地亚哥分校的研究人员服务了18年所有UCSD研究人员都可以访问它， 目前在校园内拥有200多个注册用户实验室。核心享受 来自教师和我们的机构领导的大力支持。核心小组目前的12个仪器阵列 包括多个共焦系统，多光子，光片，Gatan 3View系列块面扫描EM，幻灯片 扫描，以及其他。在尖端的超分辨率活细胞领域存在着迫切的需求 这是目前国内所缺乏的。目前，我们唯一的超分辨率系统是点 扫描共焦平台，其是缓慢且严重光漂白的样品。在这里，我们寻求资金， 从蔡司购买配备Lattice SIM 2的Elyra 7系统，作为我们主要的超分辨率活细胞成像 系统该系统还可用于对发育中的模式生物和厚的固定标本进行成像。的 与经典SIM（结构照明显微镜）相比，采样效率突破性地提高了2倍 在穿透深度实现快速、温和的3D超分辨率成像，与点扫描共聚焦成像不相上下 显微镜我们的现场仪器演示验证了最初的Elyra 7系统与莱迪思SIM（版本 1)作为超分辨率活细胞成像的实用解决方案，它还具有一些创新性 进一步提高速度和通用性的处理模式。随着最近推出的双 迭代重建算法，新升级的Elyra 7 Lattice SIM 2大大改善了 系统的分辨率从120 nm XY和300 nm Z到显著的60 nm XY和200 nm Z。的 升级的SIM 2系统也更灵活，需要更少的相移用于图像重建。我们 拟议的用户实验室说明了当地调查人员对拟议系统的迫切需求， 国家卫生研究院资助的研究他们来自校园的各个角落，他们的研究项目集体 涵盖了一系列生物医学研究领域，代表了许多疾病领域，包括癌症，糖尿病， 心血管、肺、代谢、感染、炎症、神经和精神疾病， 他人如果获得资助，Elyra 7 Lattice SIM 2技术平台将被提议的用户广泛使用。 此外，由于我们的核心已被证明能够传播， 尖端的显微镜技术，以广泛的当地研究社区。足够的空间和 基础设施，有能力的工作人员，强大的教师监督，以及强有力的机构承诺，沿着一个轨道 引用方案主导核心赠款的记录将确保有效和高效地使用拟议的 在未来的几年里，仪器。Elyra 7 Lattice SIM 2系统将填补我们仪器仪表的一个空白 投资组合，并在加州大学圣地亚哥分校的生物医学研究组合产生持续，强大的影响。

PROJECT SUMMARY / ABSTRACT The UCSD School of Medicine Microscopy Core is the largest light microscopy core facility on campus and has been serving UCSD researchers for 18 years. It is accessible by all UCSD researchers regardless of department affiliation and currently has over 200 registered user labs across the campus. The Core enjoys strong support from the faculty and our institutional leadership. The current array of 12 instruments at the Core includes multiple confocal systems, multiphoton, light sheet, Gatan 3View serial block face scanning EM, slide scanning, as well as others. A critical need exists in the realm of cutting-edge super-resolution live cell imaging, which is currently lacking locally. At the moment, our only super-resolution systems are point scanning confocal platforms which are slow and heavily photo-bleach samples. Here we seek funding to acquire an Elyra 7 system with Lattice SIM2 from Zeiss as our primary super-resolution live cell imaging system. This system can also be used to image developing model organisms and thick fixed specimens. The groundbreaking 2-fold increase in sampling efficiency over classic SIM (Structured Illumination Microscopy) enables fast, gentle 3D super-resolution imaging at penetrating depths on par with point scanning confocal microscopy. Our on-site instrument demonstration validated the initial Elyra 7 system with Lattice SIM (Version 1) as a practical solution for super-resolution live cell imaging, which also comes with some innovative processing modalities that further enhance speed and versatility. With the recent introduction of the dual iterative reconstruction algorithm, the newly upgraded Elyra 7 Lattice SIM2 has substantially improved the resolution of the system from 120 nm XY and 300 nm Z to a remarkable 60 nm XY and 200 nm Z. The upgraded SIM2 system is also more flexible requiring fewer phase shifts for image reconstruction. Our proposed user labs illustrate a critical need among the local investigators for the proposed system in advancing their NIH-funded research. They come from all corners of the campus, and their research programs collectively cover a range of biomedical research fields with many disease areas represented, including cancer, diabetes, cardiovascular, pulmonary, metabolic, infectious, inflammatory, neurological and psychiatric diseases among others. If funded, the Elyra 7 Lattice SIM2 technology platform will be extensively utilized by proposed users and additionally will reach a potentially much larger user base as our core has proven capable of disseminating cutting-edge microscopy technologies to the wide local research community. Adequate space and infrastructure, capable staff, robust faculty oversight, and strong institutional commitment along with a track record of program-leading core grant citations will ensure the effective and efficient use of the proposed instrument for years to come. The Elyra 7 Lattice SIM2 system will fill a current void in our instrumentation portfolio and generate a sustained, powerful influence on the biomedical research portfolio at UC San Diego.